{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:28:26Z","timestamp":1789709306197,"version":"4.0.1"},"reference-count":49,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,12,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Chemotherapy combinations have been the backbone of therapy for follicular lymphoma, and are associated with high initial response rates. Unfortunately, toxicity and secondary malignancies remain concerns, and most advanced-stage patients still relapse within 5 years, regardless of the regimen. Advances in the understanding of lymphoma biology have resulted in a new generation of noncytotoxic therapeutics with significant activity in follicular lymphoma. Recent studies exploring biological and targeted combinations in the frontline have shown promise, with response rates similar to chemotherapy. However, these regimens are also associated with significant cost as well as a unique toxicity profile. Large randomized studies are underway to compare noncytotoxic regimens with chemotherapy in the frontline, and several new combinations are being tested in the phase 2 setting. Ongoing work to identify predictive biomarkers and investment in mechanistic studies will ultimately lead to the personalization of therapy in the frontline setting for follicular lymphoma.<\/jats:p>","DOI":"10.1182\/asheducation-2016.1.277","type":"journal-article","created":{"date-parts":[[2016,12,2]],"date-time":"2016-12-02T16:05:27Z","timestamp":1480694727000},"page":"277-283","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":12,"title":["Frontline strategy for follicular lymphoma: are we ready to abandon chemotherapy?"],"prefix":"10.1182","volume":"2016","author":[{"given":"Nathan","family":"Fowler","sequence":"first","affiliation":[{"name":"Department of Lymphoma\/Myeloma, MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111704133996600_B1","unstructured":"http:\/\/seer.cancer.gov\/statfacts\/html\/nhl.html. Accessed 1 October 2016."},{"key":"2019111704133996600_B2","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4614-5197-6_22","article-title":"Indolent B-cell non-Hodgkin lymphomas","volume-title":"Sixty Years of Survival Outcomes at The University of Texas MD Anderson Cancer Center","author":"Neelapu","year":"2013"},{"issue":"33","key":"2019111704133996600_B3","doi-asserted-by":"crossref","first-page":"8447","DOI":"10.1200\/JCO.2005.03.1674","article-title":"New treatment options have changed the survival of patients with follicular lymphoma","volume":"23","author":"Fisher","year":"2005","journal-title":"J Clin Oncol"},{"issue":"9383","key":"2019111704133996600_B4","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","article-title":"Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial","volume":"362","author":"Ardeshna","year":"2003","journal-title":"Lancet"},{"key":"2019111704133996600_B5","first-page":"a019","article-title":"Preliminary results of quality of life analyses from the Intergroup phase III randomized trial of rituximab vs. a watch and wait approach in patients with advanced stage, asymptomatic, non-bulky follicular lymphoma","volume":"22","author":"Ardeshna","year":"2011","journal-title":"Ann Oncol"},{"issue":"1","key":"2019111704133996600_B6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1200\/jco.2003.05.128","article-title":"Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B","volume":"21","author":"Peterson","year":"2003","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111704133996600_B7","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1200\/JCO.2003.07.133","article-title":"Treatment of indolent B-Cell nonfollicular lymphomas: final results of the LL01 randomized trial of the Gruppo Italiano per lo Studio dei Linfomi","volume":"21","author":"Baldini","year":"2003","journal-title":"J Clin Oncol"},{"issue":"9873","key":"2019111704133996600_B8","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"2019111704133996600_B9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/annonc\/5.suppl_2.S73","article-title":"Intensive conventional-dose chemotherapy for stage IV low-grade lymphoma: high remission rates and reversion to negative of peripheral blood bcl-2 rearrangement","volume":"5","author":"McLaughlin","year":"1994","journal-title":"Ann Oncol"},{"issue":"10","key":"2019111704133996600_B10","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1200\/JCO.2005.03.3696","article-title":"Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center","volume":"24","author":"Liu","year":"2006","journal-title":"J Clin Oncol"},{"issue":"13","key":"2019111704133996600_B11","doi-asserted-by":"crossref","first-page":"4351","DOI":"10.1182\/blood-2001-12-0269","article-title":"Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma","volume":"100","author":"Tsimberidou","year":"2002","journal-title":"Blood"},{"key":"2019111704133996600_B12","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mds177","article-title":"Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up","volume-title":"Ann Oncol","author":"Colombat","year":"2012"},{"issue":"29","key":"2019111704133996600_B13","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1200\/JCO.2010.28.4786","article-title":"Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35\/98","volume":"28","author":"Martinelli","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111704133996600_B14","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"issue":"12","key":"2019111704133996600_B15","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","article-title":"Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"issue":"15","key":"2019111704133996600_B16","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","article-title":"Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study","volume":"25","author":"Herold","year":"2007","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111704133996600_B17","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1200\/JCO.2012.45.0866","article-title":"R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi","volume":"31","author":"Federico","year":"2013","journal-title":"J Clin Oncol"},{"issue":"19","key":"2019111704133996600_B18","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2019111704133996600_B19","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1200\/JCO.2012.41.7527","article-title":"Curability of advanced indolent or low-grade follicular lymphomas: time for a new paradigm?","volume":"31","author":"Cabanillas","year":"2013","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"2019111704133996600_B20","article-title":"10-year remission rates following rituximab (R) and FND chemotherapy (fludarabine, mitoxantrone, dexamethasone) with interferon (IFN) maintenance in indolent lymphoma: Results of a randomized study [abstract]","volume":"32","author":"Nastoupil","year":"2014","journal-title":"J Clin Oncol"},{"issue":"18","key":"2019111704133996600_B21","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1200\/JCO.2006.09.8327","article-title":"Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up","volume":"25","author":"Rohatiner","year":"2007","journal-title":"J Clin Oncol"},{"issue":"26","key":"2019111704133996600_B22","doi-asserted-by":"crossref","first-page":"6373","DOI":"10.1182\/blood-2012-03-417808","article-title":"Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results","volume":"119","author":"Khouri","year":"2012","journal-title":"Blood"},{"issue":"8","key":"2019111704133996600_B23","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/bmt.2012.182","article-title":"Reappraising the role of autologous transplantation for indolent B-cell lymphomas in the chemoimmunotherapy era: is it still relevant?","volume":"48","author":"Hamadani","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"2019111704133996600_B24","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.1998.16.8.2780","article-title":"New approach to classifying non-Hodgkin\u2019s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin\u2019s Lymphoma Classification Project","volume":"16","author":"Armitage","year":"1998","journal-title":"J Clin Oncol"},{"issue":"17","key":"2019111704133996600_B25","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood-2015-11-624288","article-title":"Follicular lymphoma: evolving therapeutic strategies","volume":"127","author":"Kahl","year":"2016","journal-title":"Blood"},{"issue":"29","key":"2019111704133996600_B26","doi-asserted-by":"crossref","first-page":"12747","DOI":"10.1073\/pnas.1002057107","article-title":"B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression","volume":"107","author":"Irish","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"2019111704133996600_B27","doi-asserted-by":"crossref","first-page":"4887","DOI":"10.4049\/jimmunol.1300179","article-title":"Nonstereotyped lymphoma B cell receptors recognize vimentin as a shared autoantigen","volume":"190","author":"Cha","year":"2013","journal-title":"J Immunol"},{"issue":"6","key":"2019111704133996600_B28","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.molimm.2007.10.009","article-title":"Remarkable selective glycosylation of the immunoglobulin variable region in follicular lymphoma","volume":"45","author":"McCann","year":"2008","journal-title":"Mol Immunol"},{"key":"2019111704133996600_B29","first-page":"553","article-title":"Targeting B-cell receptor signaling: changing the paradigm","volume-title":"Hematol Am Soc Hematol Educ Program","author":"Fowler","year":"2013"},{"issue":"5","key":"2019111704133996600_B30","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3324\/haematol.2015.139493","article-title":"Role of the tumor microenvironment in mature B-cell lymphoid malignancies","volume":"101","author":"Fowler","year":"2016","journal-title":"Haematologica"},{"issue":"21","key":"2019111704133996600_B31","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells","volume":"351","author":"Dave","year":"2004","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111704133996600_B32","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1093\/annonc\/mdr620","article-title":"Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness","volume":"23","author":"Czuczman","year":"2012","journal-title":"Ann Oncol"},{"issue":"21","key":"2019111704133996600_B33","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1002\/cncr.28299","article-title":"A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701","volume":"119","author":"Grant","year":"2013","journal-title":"Cancer"},{"issue":"25","key":"2019111704133996600_B34","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1200\/JCO.2014.59.5363","article-title":"Mechanisms of action of lenalidomide in B-cell non-Hodgkin lymphoma","volume":"33","author":"Gribben","year":"2015","journal-title":"J Clin Oncol"},{"key":"2019111704133996600_B35","article-title":"Lenalidomide and rituximab for untreated indolent lymphoma: final results of a phase II study [abstract]","volume-title":"Blood","author":"Fowler","year":"2012"},{"issue":"suppl","key":"2019111704133996600_B36","article-title":"CALGB 50803 (Alliance): A phase II trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma [abstract]","volume":"32","author":"Martin","year":"2014","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111704133996600_B37","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N Engl J Med"},{"issue":"21","key":"2019111704133996600_B38","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1182\/blood-2015-03-633156","article-title":"Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed\/refractory indolent lymphoma","volume":"125","author":"Cheah","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2019111704133996600_B39","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J Clin Oncol"},{"key":"2019111704133996600_B40","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.800.800","article-title":"Ibrutinib monotherapy in relapsed\/refractory follicular lymphoma (FL): preliminary results of a phase 2 consortium (P2C) trial [abstract]","volume-title":"ASH Annu Meet Abstr","author":"Bartlett","year":"2014"},{"key":"2019111704133996600_B41","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1182\/blood.V126.23.3998.3998","article-title":"Ibrutinib enhances the activity of anti-CD20 antibodies in an MCL mouse model: effect of drug at clinically relevant concentrations on ADCC and ADCP","volume":"126","author":"Ng","year":"2015","journal-title":"Blood"},{"key":"2019111704133996600_B42","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1182\/blood.V126.23.470.470","article-title":"Ibrutinib plus rituximab in treatment-naive patients with follicular lymphoma: results from a multicenter, phase 2 study","volume":"126","author":"Fowler","year":"2015","journal-title":"Blood"},{"key":"2019111704133996600_B43","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1182\/blood.V126.23.471.471","article-title":"Phase I study of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma (Alliance 051103)","volume":"126","author":"Ujjani","year":"2015","journal-title":"Blood"},{"key":"2019111704133996600_B44","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.799.799","article-title":"Rituximab plus lenalidomide improves the complete remission rate in comparison with rituximab monotherapy in untreated follicular lymphoma patients in need of therapy: primary endpoint analysis of the randomized phase 2 trial SAKK 35\/10 [abstract]","volume-title":"ASH Annual Meeting","author":"Kimby","year":"2014"},{"key":"2019111704133996600_B45","article-title":"Rituximab plus sargramostim for the treatment of newly diagnosed follicular lymphoma: final results of a phase II study [abstract]","volume-title":"ICML","author":"Fowler","year":"2012"},{"key":"2019111704133996600_B46","article-title":"Speed bumps on the road to a chemotherapy-free world for lymphoma patients","volume-title":"Blood","author":"Cheson","year":"2016"},{"issue":"1","key":"2019111704133996600_B47","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1470-2045(13)70551-5","article-title":"Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial","volume":"15","author":"Westin","year":"2014","journal-title":"Lancet Oncol"},{"issue":"10","key":"2019111704133996600_B48","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1016\/j.molonc.2015.10.009","article-title":"Cancer immunotherapy: Strategies for personalization and combinatorial approaches","volume":"9","author":"Sathyanarayanan","year":"2015","journal-title":"Mol Oncol"},{"issue":"suppl","key":"2019111704133996600_B49","article-title":"Evaluation of complete response rate at 30 months (CR30) as a surrogate for progression-free survival (PFS) in first-line follicular lymphoma (FL) studies: Results from the prospectively specified Follicular Lymphoma Analysis of Surrogacy Hypothesis (FLASH) analysis with individual patient data (IPD) of 3,837 pts [abstract]","volume":"33","author":"Sargent","year":"2015","journal-title":"J Clin Oncol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2016\/1\/277\/1251208\/hem088364.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2016\/1\/277\/1251208\/hem088364.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T09:14:00Z","timestamp":1573982040000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2016\/1\/277\/21093\/Frontline-strategy-for-follicular-lymphoma-are-we"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,2]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12,2]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2016.1.277","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,2]]}}}